FDA Approves Neuralstem, Inc. to Begin Phase I Spinal Cord Injury Clinical Trial

Neuralstem, Inc. just announced that they have received approval from the FDA to start a safety trial of the company’s potential stem cell therapy in people with chronic spinal cord injury. This announcement comes on the heels of the completion of Neuralstem’s Phase I trial, which was designed to test the safety of injecting human stem cells directly into the spinal cord of people with ALS. In addition, the NIH has already agreed to fund a majority of the Phase II portion of the clinical trial, which will further examine this potential stem cell therapy in people with ALS. Neuralstem, Inc. plans to begin recruiting for the Phase II trial once their protocol is approved by the FDA.

Click here to read more.

Share this: